Biotechnology firm Adcentrx Therapeutics and AvantGen have formed a three-year, multi-target partnership for the discovery of antibodies to be developed into new antibody drug conjugate (ADC) therapeutic candidates.
Nurosene Health, through its subsidiary NetraMark, has collaborated with Cyclica for the development of new drugs to treat neurodegenerative diseases.
Seismic Therapeutic has raised $101m in Series A financing led by Lightspeed Venture Partners to advance its first two lead drug programmes to the clinic.
Healx, an AI-powered, technology company involved in the next generation of drug discovery, has secured an exclusive option to license rights to develop and commercialize gaboxadol from biopharmaceutical company Ovid Therapeutics.
The National Health Service (NHS) in England has announced that Dostarlimab, a drug to treat advanced womb cancer, will be rolled out for women in the country.
Mersana Therapeutics and Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, have entered into a research collaboration and license agreement for the discovery of new antibody-drug conjugates (ADCs) for three targets.
Biopharmaceutical company Alvotech and BiosanaPharma have signed an exclusive global licensing agreement for the co-development of a proposed biosimilar, AVT23 (also called BP001), to Xolair (omalizumab).
US-based Ocugen has signed a letter of intent (LOI) to acquire Liminal Biosciences’ manufacturing site located in Belleville, Ontario, Canada, for an undisclosed sum.
Twist Bioscience has teamed up with Artisan Development Labs to discover new antibodies against five undisclosed targets.
Prellis Biologics and Bristol Myers Squibb have signed a multi-target collaboration and license agreement to discover antibodies.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.